Xu Liu

8PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 01, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.

|Apr 15, 2026
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.

|Mar 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.

Jiawei Lv, Dan-Xue Zheng, Jin-Hui Liang

|Mar 06, 2026
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.

Sai-Wei Huang, Ye-Lin Liang, Ya-Lan Tao

|Feb 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.

Ling-Long Tang, Lin Chen, Gui-Qiong Xu

|Oct 22, 2024
Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.

Sai-Wei Huang, Wei Jiang, Sha Xu

Pageof 2

Frequent Collaborators

8 joint publications

Jun Ma

7 joint publications

Linglong Tang

6 joint publications

Ying Sun

5 joint publications

Na Liu